Known vs Unknown Long-Term Risks

Three different statements people confuse

Absence of evidence is not evidence of safety. A small or short study can miss rare, delayed or cumulative effects.

How short and small the human record often is

• CJC-1295. Two randomized, placebo-controlled trials in healthy adults lasted 28 and 49 days. No serious adverse reactions were reported, and growth hormone and IGF-I levels rose. [1] Hormone levels are biomarkers, not health outcomes, and these trials did not follow people for years. FDA separately says it identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited. [2]
• Ipamorelin. In a phase 2 trial of 117 enrolled bowel-surgery patients, treatment of up to 7 days was well tolerated and showed no significant difference from placebo on the main outcome; the authors called the study small. [3] FDA separately cites a published study in which serious adverse events including death occurred when ipamorelin was given intravenously for gastric motility. [2]
• BPC-157. A 2025 systematic review included 36 studies, 35 of them preclinical, and said no clinical safety data were found. [4] A 2026 systematic review found three human studies totaling 30 participants, rated them poor quality and rated certainty of evidence very low. [5]
• Growth hormone secretagogues (review). A review found few long-term, rigorously controlled studies, found available studies indicated they were well tolerated with some concern for higher blood glucose, and called for study of long-term effects including cancer incidence and mortality. [6]

None of these should be read as "safe because small studies found no problems." Reading across them, the pattern is short follow-up, few people and substitute markers.

Even approved products have unknowns

After approval, FDA says it is impossible to have complete information about a drug's safety, and the picture evolves over months and years. [7] The tesamorelin label, for instance, states that long-term cardiovascular safety has not been established. [8] A label is a record of what is known so far.

Questions that matter for any peptide

• Which exact molecule and product? Identity can be uncertain for names sold online; see research peptide naming and identity problems.
• What population and how long? Healthy volunteers for weeks do not show what happens to people with other conditions over years.
• What was measured? A hormone level or tissue change is not a clinical outcome.
• Was the tested product the same as what is sold? Quality varies; see endotoxins, purity and sterility.
• Who has been left out? Pregnancy, children, cancer and diabetes are often not studied. The tesamorelin label contraindicates pregnancy and active malignancy and warns of glucose intolerance and, in children with open growth plates, possible excessive growth. [8]

What a 2026 review concluded

A structured review of injectable peptides in sports medicine reported that clinical adoption has outpaced high-quality evidence, that regenerative and growth-hormone-axis peptides remain investigational with uncertain safety profiles, and that product quality is a concern. [9]

Related guides

See peptide safety overview, approved medicines vs experimental products and claim check: "peptides are natural, so they are safe".